1	Wastewater Monitoring of SARS-CoV-2 from Acute Care Hospitals Identifies Nosocomial
2	<b>Transmission and Outbreaks</b>
3	
4	Nicole Acosta <sup>1</sup> , María A. Bautista <sup>2</sup> , Jordan Hollman <sup>3,4</sup> , Janine McCalder <sup>1,2</sup> , Alexander Buchner
5	Beaudet <sup>2</sup> , Lawrence Man <sup>2</sup> , Barbara J. Waddell <sup>1</sup> , Jianwei Chen <sup>2</sup> , Carmen Li <sup>2</sup> , Darina Kuzma <sup>5</sup> ,
6	Srijak Bhatnagar <sup>2</sup> , Jenine Leal <sup>1,6,7,10</sup> , Jon Meddings <sup>8</sup> , Jia Hu <sup>7,9,10</sup> , Jason L. Cabaj <sup>7-10</sup> , Norma J.
7	Ruecker <sup>11</sup> , Christopher Naugler <sup>7,12</sup> , Dylan R. Pillai <sup>1,12-14</sup> , Gopal Achari <sup>4</sup> , M. Cathryn Ryan <sup>3</sup> , John
8	M. Conly <sup>1,6,8,10,12,13</sup> , Kevin Frankowski <sup>5</sup> , Casey RJ Hubert <sup>2</sup> and Michael D. Parkins <sup>1,8,13</sup>
9	
10	<sup>1</sup> Department of Microbiology, Immunology and Infectious Diseases, University of Calgary,
11	Calgary, Canada
12	<sup>2</sup> Department of Biological Sciences, University of Calgary, Calgary, Canada
13	<sup>3</sup> Department of Geosciences, University of Calgary, Calgary, Canada
14	<sup>4</sup> Department of Civil Engineering, University of Calgary, Calgary, Canada
15	<sup>5</sup> Advancing Canadian Wastewater Assets, University of Calgary, Calgary, Canada
16	<sup>6</sup> Infection Prevention and Control, Alberta Health Services, Calgary, Canada
17	<sup>7</sup> Department of Community Health Sciences, University of Calgary, Calgary, Canada
18	<sup>8</sup> Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary,
19	Canada

20	<sup>9</sup> Provincial Population	& Public Health	, Alberta Health	Services,	Calgary,	Canada
----	------------------------------------	-----------------	------------------	-----------	----------	--------

- <sup>10</sup> O'Brien Institute for Public Health, University of Calgary, Calgary, Canada
- <sup>11</sup> Water Quality Services, City of Calgary, Calgary, Canada
- <sup>12</sup> Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada
- <sup>13</sup> Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada
- <sup>14</sup> Alberta Precision Laboratories, Alberta Health Services, Calgary, Canada

26

- 27 Key words: COVID-19, sewage, wastewater, wastewater-based epidemiology, hospital-acquired
- 28 **Running Title:** SARS-CoV-2 in Hospital Wastewaters
- 29 Abstract word count: 246
- 30 Manuscript word count: 2998
- **Figures:** 2
- **Tables:** 3
- 33 Supplemental Material included

#### 34 Key-points summary:

- 35 SAS-CoV-2 RNA is detectable in hospital wastewater. Wastewater SARS-CoV-2 RNA increases
- 36 in conjunction with COVID-19-related hospitalizations. Spikes in SARS-CoV-2 wastewater signal
- 37 correspond to incident hospital-acquired cases and outbreaks, suggesting passive surveillance via
- 38 wastewater has great promise for COVID-19 monitoring.

## **39 \*Corresponding author:**

- 40 Michael D. Parkins, Associate Professor, University of Calgary.
- 41 Postal address: 3330 Hospital Drive, NW, Calgary, Alberta, T2N 4N1. CANADA.
- 42 e-mail: mdparkin@ucalgary.ca
- 43 Phone: 403-220-5951, Fax: 403-270-2772.
- 44

## 45 Alternative corresponding author:

- 46 Casey RJ Hubert, Associate Professor, University of Calgary
- 47 Postal address: 2500 University Gate NW, Calgary, AB T2N 1N4. CANADA
- 48 e-mail: chubert@ucalgary.ca
- 49 Phone: 403-220-7794, Fax 403-289-9311
- 50
- 51

### 52 ABSTRACT

Background: SARS-CoV-2 has been detected in wastewater and its abundance correlated with
community COVID-19 cases, hospitalizations and deaths. We sought to use wastewater-based
detection of SARS-CoV-2 to assess the epidemiology of SARS-CoV-2 in hospitals.

Methods: Between August and December 2020, twice-weekly wastewater samples from three 56 tertiary-care hospitals (totaling >2100 dedicated inpatient beds) were collected. Wastewater 57 samples were concentrated and cleaned using the 4S-silica column method and assessed for SARS-58 59 CoV-2 gene-targets (N1, N2 and E) and controls using RT-qPCR. Wastewater SARS-CoV-2 as measured by quantification cycle (Cq), genome copies and genomes normalized to the fecal 60 biomarker PMMoV were compared to the total daily number of patients hospitalized with active 61 62 COVID-19, confirmed cases of hospital-acquired infection, and the occurrence of unit-specific outbreaks. 63

Results: Of 165 wastewater samples collected, 159 (96%) were assayable. The N1-gene from 64 SARS-CoV-2 was detected in 64.1% of samples, N2 in 49.7% and E in 10%. N1 and N2 in 65 wastewater increased over time both in terms of amount of detectable virus and the proportion of 66 samples that were positive, consistent with increasing hospitalizations (Pearson's r=0.679, 67 P<0.0001, Pearson's r=0.728, P<0.0001, respectively). Despite increasing hospitalizations through 68 the study period, wastewater analysis was able to identify incident nosocomial-acquired cases of 69 COVID-19 (Pearson's r =0.389, P<0.001) and unit-specific outbreaks by increases in detectable 70 71 SARS-CoV-2 N1-RNA (median 112 copies/ml) versus outbreak-free periods (0 copies/ml; P<0.0001). 72

- 73 Conclusions: Wastewater-based monitoring of SARS-CoV-2 represents a promising tool for
- 74 SARS-CoV-2 passive surveillance and case identification, containment, and mitigation in acute-
- 75 care medical facilities.

#### 77 INTRODUCTION

SARS-CoV-2 RNA is present in the feces of infected individuals – appearing just prior or concomitant with symptoms[1]. Accordingly, leaders in the field of wastewater-based epidemiology leveraged their expertise to study this emerging infectious disease[2, 3]. Medema *et al* first reported SARS-CoV-2-RNA in Dutch wastewater-treatment plants (WW-TP)[4]. Several groups have since adapted this technology to understand community disease-burden[5-8]. Recent studies suggest that SARS-CoV-2-RNA increases in WW-TP precede clinically diagnosed cases by 0-2 days and associated hospitalizations by 1-4 days[6].

Between 4-8% of individuals with COVID-19 will be hospitalized, with age and co-morbidities 85 being key risk factors[9-11]. Nosocomial-transmission and outbreaks affecting patients and health 86 care workers (HCW) are not uncommon, although drivers remain to be fully understood[12, 13]. 87 While hospital-acquisition is rare (0.8-5 cases/10,000 patient-days in communities with high 88 disease burden), public fear of acquiring COVID-19 from hospitals has resulted in reduced health-89 resource utilization and hospital avoidance, often to the detriment of patients [14, 15]. Accordingly, 90 hospital-based detection tools are needed to understand the epidemiology of COVID-19 and 91 92 potentially mitigate spread.

Hospitals hold great promise in understanding SARS-CoV-2 wastewater-generated data. Owing to their proximity to affected individuals in the municipal sewershed relative to WW-TP (i.e., shorter transit time for signal degradation[1]), hospitals may aid in understanding SARS-CoV-2 wastewater dynamics. Compared to the general community, hospitals are much more likely to comprehensively monitor and identify all cases within their populations. Furthermore, outbreaks in hospitals are rapidly and comprehensively investigated. For these reasons we embarked on this

99 study to determine relationships between hospital SARS-CoV-2 wastewater dynamics and
100 COVID-19 hospitalizations, nosocomial-transmissions and outbreaks.

## 101 METHODS

#### 102 Acute-care hospitals and hospital information systems

We monitored SARS-CoV-2-RNA in the wastewater from three of Calgary's four adult tertiary-103 care hospitals, accounting for 89% of staffed-inpatient beds (Supplementary Material). Daily 104 prevalent-hospitalized cases were defined as those with laboratory-confirmed COVID-19 within 105 14 days, remaining on contact/droplet precautions. Hospital-acquired cases were defined as 106 107 patients who were admitted to hospital  $\geq$ 7 days before COVID-19 symptom onset that were then confirmed by a positive RT-qPCR SARS-CoV-2 test; or a patient admitted to hospital for  $\leq 7$  days 108 confirmed to have hospital-acquired COVID-19 infection based on an epidemiological link. 109 Hospital-acquired cases were separately recorded including the unit where they were acquired and 110 are reported as hospital-wide signals for Hospital-1 and 2. Data for Hospital-3 are presented as 3A, 111 112 3B, 3C based on wastewater drainage outflows of different units. COVID-19 outbreaks were defined as any unit with  $\geq 1$  confirmed hospital-acquired case(s) and/or  $\geq 2$  confirmed COVID-19 113 cases in HCWs linked to a unit. This research was approved by the University of Calgary's 114 115 Conjoint Health Regional Ethics Board (REB-20-1252).

#### 116 Wastewater sampling

Wastewater samples were collected from August 5<sup>th</sup> to December 17<sup>th</sup>, 2020 at three hospitals. Hospital-wide access through a single sampling point was not possible at Hospital-3 where an initial sampling point (Hospital-3A) captured the units predicted to be most relevant for COVID-19 (including ICUs and dedicated COVID-19 care-units). Beginning October 1<sup>st</sup> two additional

sites were added, Hospital-3B and Hospital-3C, expanding coverage to all inpatient-care buildings.
Composite 24-hour samples of wastewater were collected using ISCO-GLS autosamplers
(Lincoln, Nebraska) placed inside sewer access points outside of hospitals. Samples were taken
from each location twice-weekly.

#### 125 Sample Processing and RNA Purification

Sample preparation and molecular analysis were performed at separate sites to prevent cross 126 contamination. At ACWA, wastewater samples were processed with a 40 ml aliquot taken to 127 comprise the sample. Each sample was spiked with a positive control - Bovilis® attenuated-128 Coronavirus Vaccine (BCoV; Merck, #151921). Sample processing and RNA purification was 129 conducted using the 4S-silica column method (i.e., Sewage, Salt, Silica and SARS-CoV-2) with 130 modifications[16]. Purified nucleic acids were transported on dry ice to the Health Sciences Centre 131 for molecular analysis. An extraction blank control was included for every processed sample batch 132 133 to ensure no contamination occurred.

### 134 **RT-qPCR analysis**

135 We used RT-qPCR to quantify SARS-CoV-2-RNA and controls in wastewater. Specific primers and probes (Supplementary Table-S1) were used to amplify two regions of the nucleocapsid gene 136 (i.e., N1 and N2) and a region of the envelope gene (i.e., E). Samples were considered positive for 137 the presence of SARS-CoV-2 RNA-target if amplification passed a detection cycle threshold in 138 <40 cycles for at least one of N1, N2 and/or E [4, 17, 18]. The quantification cycle (Cq) value was 139 used for calculations when this threshold was <40 cycles or reached between 40 and 45 cycles for 140 one target as long as another target reached the threshold in <40 cycles. Amplification of the 141 Pepper mild mottle virus (PMMoV) was employed to incorporate a human fecal biomarker control 142

in order to normalize SARS-CoV-2 for the relative bioburden in samples[5]. RT-qPCR was
performed using a QuantStudio-5 Real-Time PCR System (Applied Biosystems) with each run
including no-template controls (NTCs) in triplicate. For N1, N2 and E-assays three positive
controls were included in each run. Samples where minimal signal for BCoV or PMMoV controls
were recovered were excluded from the analysis to mitigate false-negative results. Amplified
products from wastewater were also Sanger sequenced to confirm amplicons were derived from
SARS-CoV-2.

#### 150 Statistical analysis

To compare the surrogate BCoV and PMMoV signals between hospitals, pairwise Mann-Whitney 151 tests were performed. Non-parametric Kruskal-Wallis tests were performed for multiple 152 comparisons of assay sensitivity and surrogate organism signals between sampling locations. 153 Pearson's correlation analyses were performed to determine the correlation of wastewater RNA-154 signal measured as i). Cq, or ii). genome copies/ml of wastewater or iii). genome copies/genome 155 of PMMoV, vs daily-hospitalized cases. To assess for correlation of wastewater RNA-signal with 156 incident hospital-acquired cases, and to compensate for gaps owing to the twice-weekly sampling, 157 incident cases occurring +/- 3 days were compared to wastewater signals. To compare the SARS-158 CoV-2 wastewater N1-signal observed during and between unit-outbreaks, each sample was 159 dichotomized as being collected within 3-days of a declared outbreak or not. Samples after a 160 declared outbreak were excluded until 3-days after the last in-hospital linked case was identified. 161 Statistical tests analyzed Hospital-1 and Hospital-2 together (given their capture of the entire 162 163 hospital-facility) and separately. Statistical analyses were conducted with GraphPad's Prism-8 software (La Jolla, CA). 164

#### 165 **RESULTS**

### 166 Hospital SARS-CoV-2 Wastewater-RNA Kinetics

In total, 165 hospital wastewater samples were collected and 159 assessed through 135-days of bi-167 weekly observation (40 Hospital-1; 39 Hospital-2; 34 Hospital-3A; 23 Hospital-3B; 23 Hospital-168 169 3C). Six samples were excluded (Supplementary Figures S1-S2) SARS-CoV-2-RNA in wastewater increased over time in both the amount detectable and the proportion of samples that 170 were positive, consistent with increasing cases and hospitalizations (Table 1, Supplementary 171 Figure S3), coinciding with Calgary's COVID-19 'second wave'. We observed that the N1-assay 172 had the best sensitivity for detecting SARS-CoV-2. Of the 96 samples tested using N1, N2 and E-173 assays (i.e., those received between August 1<sup>st</sup> and October 29<sup>th</sup>), 9 samples were positive for all 174 three targets, 28 were positive only for N1 and N2, and 39 were positive only for N1. After October 175 29<sup>th</sup> the E-assay was dropped, and 69 samples were analyzed, 51 were positive for both N1 and 176 177 N2 and 63 were positive just with N1. N1 and N2-signals measured as Cq were positively correlated (Pearson's r=0.710 Hospital-1, 0.762 Hospital-2, 0.792 Hospital-3A, 0.417 Hospital-178 3B and 0.491 Hospital-3C) across all sites (Table 2). No-template and blank controls for sample 179 180 processing and RNA purification were negative for all assays (i.e., N1, N2, E, BCoV and PMMoV). Standard curves for all RT-qPCR assays were within an acceptable range for 181 efficiencies (75 to 162%) and  $R^2$  (0.7 to 1.0) (Supplementary Table-S2). 182

Hospital-1 had a higher proportion of SARS-COV-2-positive wastewater compared to Hospital-2
and Hospital-3, consistent with the higher burden of disease in NE Calgary (Table 1 and Figure
1). Following a large outbreak in Hospital-3 involving 45 patients, 43 HCW and 5 visitors
(beginning in a ward not monitored via Hospital-3A site and compounded by affected patients

being transferred into different units through the hospital) that was declared on September 17<sup>th</sup>,
wastewater sampling was expanded to include additional sites; Hospital-3B and Hospital-3C
(Figure 2) to enable complete capture of Hospital-3.

#### 190 Wastewater SARS-CoV-2 signal correlates with total hospitalized COVID-19 cases

191 We assessed the correlation between the SARS-CoV-2 wastewater-N1 with active-COVID-19 patients on contact/droplet isolation at each hospital. When assessed together, Hospital-1 and 192 Hospital-2, we observed that as prevalent cases increased, the wastewater-signal measured as N1-193 Cq also increased (Pearson's r=0.679, CI: 0.529-0.787, P<0.0001). This was also true when 194 Hospital-1 and Hospital-2 were assessed separately (Table 2). The same was observed when 195 SARS-CoV-2-N1 wastewater was normalized against copies of the PMMoV at Hospital-2, but 196 only trended towards significance at Hospital-1 (Table 2). These same correlations are not as 197 reliable at the Hospital-3 as we did not have access to prevalent cases as a function of sampling 198 199 site. However, we continued to observe a positive correlation (Table 2) between prevalent cases vs N1-wastewater signal was measured as Cq at Hospital-3A (including dedicated COVID-19 care 200 units and ICUs) (Pearson's r=0.717) or measured as copies/ml and copies normalized to PMMoV 201 202 at Hospital-3C (Pearson's r=0.503 and 0.479, respectively).

### 203 Wastewater SARS-COV2 signal correlates with hospital-acquired infections and outbreaks

We observed a positive correlation between wastewater N1-signal and hospital-acquired cases at Hospital-1 and Hospital-2 when analyzed together (Pearson's r=0.389, CI: 0.177–0.566, P<0.001) and individually (Table 2). Hospital-3 data could not be fully analyzed as we did not have complete access to patient/HCW movements. Total SARS-CoV-2 as measured by Cq correlated with incident hospital-acquired cases at Hospital-3A when normalized relative to PMMoV. With

209 respect to whether peaks in SARS-CoV-2 in wastewater associated with outbreaks, we compared SARS-CoV-2 signal from wastewater samples collected within 3 days of an outbreak being 210 211 declared with samples collected during outbreak-free periods. When Hospital-1 and Hospital-2 were analysed together, we observed significant differences in median SARS-CoV-2 N-1 between 212 outbreak-free periods vs outbreak periods when measured as copies/ml (0 [IQR: 0-57] vs 112 213 [IQR: 12-1726], P<0.0001) and normalized for PMMoV (0 [IQR: 0-0.06] vs 0.17 [IQR: 0.06-214 0.89], P=0.0003). We observed that at each of Hospital-1, Hospital-2 and Hospital-3A there were 215 significant differences in median SARS-CoV-2-N1 measured using copies/ml between outbreak 216 and outbreak-free periods (Table 3). Similarly, the same trend was observed at Hospital-1 and 217 Hospital-3A when wastewater SARS-CoV-2-N1 was normalized for PMMoV (Table 3). 218

#### 219 DISCUSSION

Hospital-associated outbreaks of COVID-19 are increasingly being reported. Early data suggests that patients with nosocomial COVID-19 may fare worse than those with community-acquired disease, experiencing longer hospital stays but not increased mortality[13]. This observation balances the opposing impacts of increased co-morbidities and medical acuity in hospitalizedindividuals on one-hand, with the potential for earlier detection and more rapid supportive care/treatment on the other.

Preventing nosocomial transmission of COVID-19 is challenging for a myriad of reasons[19]. In addition to its highly infectious nature, accurate identification, triage, and effective isolation of cases is exceedingly difficult. While COVID-19 has a typical incubation period of 5-7 days, it can take as long as 14 days to manifest such that identifying evolving symptoms in previously admitted patients is challenging[20, 21]. Furthermore, up to 40% of individuals (including patients and

HCW) may be asymptomatic, pauci-symptomatic, or pre-symptomatic– each just as likely to transmit infection as symptomatic individuals[22-24]. Despite rigorous infection control protocols, nosocomial infections continue to occur. Novel strategies to understand the epidemiology of SARS-CoV-2 in hospitals are therefore urgently required. One such strategy may be the monitoring of hospital wastewater[25].

To date, most wastewater-based SARS-CoV-2 RNA surveillance has focused on monitoring community burden of disease by sampling WW-TP[5-8]. More recently, moving sampling 'upstream' in the wastewater-network, closer to patients, is actively being explored. The most granular data comes from single-facility assessments. Passive wastewater surveillance could hold promise as an early warning strategy, adaptable to both low- and high-risk facilities. Importantly, if an incipient signal is detected in facility-wide wastewater samples, in-building plumbing systems can be strategically sampled in a nested manner in order to confirm an outbreak location.

Here we demonstrate that both the frequency of positive samples and the abundance of SARS-CoV-2 RNA in hospital wastewater systems correlated with increasing hospitalised cases – analogous to WW-TP levels correlating with the COVID-19 community-diagnosed cases[5-8]. This was most evident using raw SARS-CoV-2 Cq values but was also evident when normalized against PMMoV levels. We observed the N1-region of the nucleocapsid gene to be more sensitive than N-2, and E so low as to be dropped from our protocol. Other groups have reported similar trends in that the N1-target is the most sensitive marker in WW-TP studies[4] and cruise ships[26].

Despite nosocomial cases and outbreaks representing a small fraction of the overall population of patients hospitalized with COVID-19, these events were discernable by wastewater testing. The natural history of SARS-CoV-2-RNA presence in the gastrointestinal tract remains incompletely

understood[2, 3]. Changes in fecal viral loads over the course of the disease have not been 253 explored. Extrapolating from our hospital-based wastewater data, it appears that peak fecal viral 254 255 shedding may occur around symptom onset, given the congruence of wastewater RNA-signal and nosocomial cases and outbreaks identified in hospitals. Based on the rapid decline in wastewater 256 signal thereafter, it is likely that fecal SARS-CoV-2-RNA drops significantly after initial 257 presentation. Indeed, early in the pandemic when fewer patients with COVID-19 were 258 hospitalized, wastewater samples routinely tested negative. This critical observation suggests that 259 wastewater-based monitoring of SARS-CoV-2 may be most sensitive for identifying incident 260 cases. Accordingly, wastewater-based monitoring of individual high-risk facilities (i.e., hospitals, 261 nursing homes and industrial meat plants) – providing more granular data - through to WW-TP 262 263 may have great merit.

264 A key limitation to the identification of SARS-CoV-2 in wastewater samples, relative to clinical samples (e.g., swabs) is the massive volume of water in which samples are diluted. This 265 necessitates sample concentration. While procedures for the efficient recovery of non-enveloped 266 viruses exist, researchers continue to search for satisfactory protocols for enveloped viruses such 267 as SARS-CoV-2[27]. Many groups have explored ways to improve the sensitivity of wastewater 268 SARS-CoV-2 detection. Diagnostic platforms with improved sensitivity and more impervious to 269 impurities in the wastewater matrix (i.e., digital droplet RT-PCR) also show considerable 270 promise[28, 29]. Sampling in the proximal sewershed may lead to day-to-day variance resulting 271 in signal noise. This is particularly true for single-facility studies where potential extremes in 272 individual virus shedding could confound results; limited data suggests significant variations in 273 fecal viral load occur (from  $10^{3.4}$  to  $10^{7.6}$ )[30]. This is a key challenge that remains to be solved if 274 wastewater data is to be used in a meaningful way. Similarly, issues arise with attempts to 275

normalize SARS-CoV-2 based on the contributing population. We chose to use the PMMoV as a
fecal biomarker to control for variations in fecal loading – a particular risk when sampling takes
place 'upstream' in the sewershed. While this marker has been validated in WW-TP samples where
large and diverse populations contribute to sewage[31], hospitals are a much smaller collection of
individuals and variations in PMMoV excretion owing to differences in diet could have a much
larger impact[32].

By capturing longitudinal data from three tertiary-care hospitals (>2100 inpatient beds) we have 282 demonstrated that passive wastewater monitoring is indeed possible at a range of hospital-283 facilities. Whereas Hospital-1 and Hospital-2 had a single municipal access point enabling 284 surveillance of the entire facility – Hospital-3 required three locations to capture fully. As patients 285 were frequently moved from one unit/building to another, either based on attending services 286 287 geographic location, COVID-positive patient cohorting or need for ICU support, attributing SARS-CoV-2 signal in the wastewater of this facility was more complicated but nonetheless 288 289 correlations were evident. Furthermore, while nursing staff is often assigned to individual units, 290 many allied health workers and physicians work or consult throughout the entire facility. If passive wastewater monitoring is to be adapted for other aspects of nosocomial surveillance (i.e., antibiotic 291 consumption, emergence of antimicrobial resistant organisms, etc.) - a keen insight into the 292 collection network is required. 293

There are limitations of our work that merit discussion. Given the complexity involved in sample collection, we were limited to twice-weekly sampling. Knowing how quickly SARS-CoV-2 can spread and outbreaks can occur, a daily monitoring strategy would have much greater capacity to identify and mitigate secondary cases of COVID-19. Incident cases are likely to be clinically diagnosed in hospital far faster than in other high-risk facilities owing to greater resources and

heightened suspicion – potentially leading to an even greater lead-time associated with a positive 299 wastewater-signal of outbreaks than observed herein. Hospitals pose unique challenges in 300 301 wastewater monitoring owing to these facilities' high use of chemical disinfectants and 302 detergents[33] that could interfere with molecular assays; this may explain why 3.6% of our samples spiked controls and PMMoV were not detected by RT-qPCR. To minimize the risk of 303 false negatives, rigorous protocols that use internal controls (such as our BCoV spike) are 304 necessary. The role of PCR-inhibitors in the wastewater matrix within the proximal sewershed is 305 an area that deserves considerable study if this field is to expand. 306

Wastewater-based monitoring can only effectively monitor those individuals that contribute fecal 307 matter to the sewershed. Importantly, hospitalized patients - those most vulnerable to COVID-19 308 adverse events - are often unable to self-toilet. Rather, these sick and often elderly individuals are 309 310 dependent on continence aids, adult diapers, sanitary pads and nursing cleanup; this results in fecal matter from these individuals being disposed into biohazard solid waste. Accordingly, wastewater-311 based sampling could miss between 10-20% of patients in general hospital patients [34, 35]. This 312 proportion is expected to be even higher in ICU where immobilization necessitated through 313 ventilatory support further heightens toileting assistance requirements. Adapting wastewater 314 surveillance technology to other high-risk settings like long-term care will encounter this same 315 limitation. Finally, - tracking workers through passive wastewater monitoring poses inherent 316 challenges. There is data that suggests that 52-56% of employees are uncomfortable defecating at 317 work[36, 37]. 318

#### 319 Conclusion

In a five-month observational study we were able to detect SARS-CoV-2 from the wastewater of 320 Calgary's three largest tertiary-care hospitals. The rate of SARS-CoV-2 wastewater test-positivity 321 322 and RNA-abundance increased over time, concomitant with the increasing proportion of patients hospitalized with COVID-19. Despite persistent low levels of SARS-CoV-2-RNA in wastewater 323 resulting from patients being treated for and recovering from COVID-19, we detected spikes 324 325 attributable to hospital-acquired infections and outbreaks. This study reveals that wastewaterbased monitoring of SARS-CoV-2 RNA holds promise for early detection, monitoring and 326 containment of incident infections. 327

# 329 FUNDING

- 330 This work was supported by grants from the Canadian Institute of Health Research [448242 to
- 331 M.D.P.]; and Canadian Foundation for Innovation [41054 to C.R.J.H], as well as discretionary
- start-up funding from the Cumming School of Medicine Infectious Disease Section-Chief Fund
- 333 (M.D.P.) and Campus Alberta Innovates Program Chair (C.R.J.H).

#### 335 ACKNOWLEDGEMENTS

The authors gratefully acknowledge the staff of the City of Calgary and in particular members of 336 Water Quality Services for their continued efforts for sample site planning, maintenance, and 337 collection. The authors are grateful to staff from Alberta Health Services and AHS Infection 338 Prevention and Control for assistance in data collection on patient disposition in the Calgary Zone. 339 The authors also thanks Cameron Semper for providing the pMCSG53 vector and T7/T7 340 341 terminator primers, and for providing support with Gibson assembly cloning. We would like to acknowledge the tremendous efforts of Dr Rhonda Clark for program administration and 342 343 management.

All authors report no potential conflicts. All authors have submitted the ICMJE Form forDisclosure of Potential Conflicts of Interest.

# 347 **REFERENCES**

348	1.	Foladori P, Cutrupi F, Segata N, et al. SARS-CoV-2 from faeces to wastewater treatment:
349		What do we know? A review. Sci Total Environ 2020; 743: 140444.
350	2.	Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel
351		coronavirus disease rehabilitation patients. Chin Med J (Engl) 2020; 133(9): 1039-43.
352	3.	Gupta S, Parker J, Smits S, Underwood J, Dolwani S. Persistent viral shedding of SARS-
353		CoV-2 in faeces - a rapid review. Colorectal Dis 2020; 22(6): 611-20.
354	4.	Medema G, Heijnen L, Elsinga G, Italiaander R, Brouwer A. Presence of SARS-
355		Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in
356		the Early Stage of the Epidemic in The Netherlands. Environ Sci Technol Lett 2020; 7:
357		511-6.
358	5.	D'Aoust PM, Mercier E, Montpetit D, et al. Quantitative analysis of SARS-CoV-2 RNA
359		from wastewater solids in communities with low COVID-19 incidence and prevalence.
360		Water Res <b>2021</b> ; 188: 116560.
361	6.	Peccia J, Zulli A, Brackney DE, et al. Measurement of SARS-CoV-2 RNA in wastewater
362		tracks community infection dynamics. Nat Biotechnol 2020; 38(10): 1164-7.
363	7.	Ahmed W, Angel N, Edson J, et al. First confirmed detection of SARS-CoV-2 in
364		untreated wastewater in Australia: A proof of concept for the wastewater surveillance of
365		COVID-19 in the community. Sci Total Environ 2020; 728: 138764.
366	8.	Wurtzer S, Marechal V, Mouchel J, et al. Evaluation of lockdown effect on SARS-CoV-2
367		dynamics through viral genome quantification in waste water, Greater Paris, France, 5
368		March to 23 April 2020. Eurosurveillance 2020; 25(50): 2000776.

505 $7$ . IOMINUM ON, LOCKE L, OLEMIT, ELMINARIA GUIDIS IOLITOSDIALIZATION, MECHAN	9. Ioannou GN. Locke E. G	Green P. et al. Risk Factors f	for Hospitalization	. Mechanica
--	---------------------------	--------------------------------	---------------------	-------------

- 370 Ventilation, or Death Among 10131 US Veterans With SARS-CoV-2 Infection. JAMA
- 371 Netw Open **2020**; 3(9): e2022310.
- 10. Carrillo-Vega MF, Salinas-Escudero G, Garcia-Pena C, Gutierrez-Robledo LM, Parra-
- 373 Rodriguez L. Early estimation of the risk factors for hospitalization and mortality by
- 374 COVID-19 in Mexico. PLoS One **2020**; 15(9): e0238905.
- 11. Ko JY, Danielson ML, Town M, et al. Risk Factors for COVID-19-associated
- 376 hospitalization: COVID-19-Associated Hospitalization Surveillance Network and
- 377 Behavioral Risk Factor Surveillance System. Clin Infect Dis **2020**.
- 12. Long DR, O'Reilly-Shah V, Rustagi AS, et al. Incidence of Health Care-Associated
- 379 COVID-19 During Universal Testing of Medical and Surgical Admissions in a Large US
  380 Health System. Open Forum Infect Dis 2020; 7(10): ofaa435.
- 13. Carter B, Collins JT, Barlow-Pay F, et al. Nosocomial COVID-19 infection: examining
- the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople). J Hosp
  Infect 2020; 106(2): 376-84.
- 14. Hartnett KP, Kite-Powell A, DeVies J, et al. Impact of the COVID-19 Pandemic on
- Emergency Department Visits United States, January 1, 2019-May 30, 2020. MMWR
- 386 Morb Mortal Wkly Rep **2020**; 69(23): 699-704.
- 387 15. Czeisler ME, Marynak K, Clarke KEN, et al. Delay or Avoidance of Medical Care
- 388 Because of COVID-19-Related Concerns United States, June 2020. MMWR Morb
- 389 Mortal Wkly Rep **2020**; 69(36): 1250-7.

390	16.	Whitney ON, Al-Shayeb B, Crits-Cristoph A, et al. V.4 -Direct wastewater RNA capture
391		and purification via the "Sewage, Salt, Silica and SARS-CoV-2 (4S). Available at:
392		https://dx.doi.org/10.17504/protocols.io.bpdfmi3n. Accessed 1 June 2020.
393	17.	Randazzo W, Truchado P, Cuevas-Ferrando E, Simón P, Allende A, Sánchez G. SARS-
394		CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area.
395		Water research <b>2020</b> ; 181: 115942.
396	18.	Wu F, Zhang J, Xiao A, et al. SARS-CoV-2 Titers in Wastewater Are Higher than
397		Expected from Clinically Confirmed Cases. mSystems 2020; 5(4): e00614-20.
398	19.	Harada S, Uno S, Ando T, et al. Control of a Nosocomial Outbreak of COVID-19 in a
399		University Hospital. Open Forum Infect Dis 2020; 7(12): ofaa512.
400	20.	Wang X, Zhou Q, He Y, et al. Nosocomial outbreak of COVID-19 pneumonia in Wuhan,
401		China. Eur Respir J <b>2020</b> ; 55(6).
402	21.	Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus
403		(2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro
404		Surveill <b>2020</b> ; 25(5).
405	22.	Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and
406		Transmission in a Skilled Nursing Facility. N Engl J Med 2020; 382(22): 2081-90.
407	23.	Yanes-Lane M, Winters N, Fregonese F, et al. Proportion of asymptomatic infection
408		among COVID-19 positive persons and their transmission potential: A systematic review
409		and meta-analysis. PLoS One 2020; 15(11): e0241536.
410	24.	Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 Transmission From People
411		Without COVID-19 Symptoms. JAMA Netw Open 2021; 4(1): e2035057.

412	25.	Gonçalves J, Koritnik T, Mioč V, et al. Detection of SARS-CoV-2 RNA in hospital	
-----	-----	---	--

- 413 wastewater from a low COVID-19 disease prevalence area. Science of The Total
- 414 Environment **2021**; 755: 143226.
- 415 26. Ahmed W, Bertsch PM, Angel N, et al. Detection of SARS-CoV-2 RNA in commercial
- 416 passenger aircraft and cruise ship wastewater: a surveillance tool for assessing the
- 417 presence of COVID-19 infected travellers. J Travel Med **2020**; 27(5).
- 418 27. Alygizakis N, Markou AN, Rousis NI, et al. Analytical methodologies for the detection
- 419 of SARS-CoV-2 in wastewater: Protocols and future perspectives. Trends Analyt Chem
- **2021**; 134: 116125.
- 421 28. Gonzalez R, Curtis K, Bivins A, et al. COVID-19 surveillance in Southeastern Virginia
  422 using wastewater-based epidemiology. Water Res 2020; 186: 116296.
- 423 29. Falzone L, Musso N, Gattuso G, et al. Sensitivity assessment of droplet digital PCR for
  424 SARS-CoV-2 detection. Int J Mol Med 2020; 46(3): 957-64.
- 425 30. Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of SARS-CoV-
- 426 2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic

427 Review and Meta-analysis. Gastroenterology **2020**; 159(1): 81-95.

- 428 31. Kitajima M, Sassi HP, Torrey JR. Pepper mild mottle virus as a water quality indicator.
  429 npj Clean Water 2018; 1(1): 19.
- 430 32. Colson P, Richet H, Desnues C, et al. Pepper mild mottle virus, a plant virus associated
- with specific immune responses, Fever, abdominal pains, and pruritus in humans. PLoS
  One 2010; 5(4): e10041.
- 433 33. Zotesso JP, Cossich ES, Janeiro V, Tavares CRG. Treatment of hospital laundry
- 434 wastewater by UV/H2O2 process. Environ Sci Pollut Res Int **2017**; 24(7): 6278-87.

435	34.	Condon M, Mannion E, Molloy DW, O'Caoimh R. Urinary and Faecal Incontinence:
436		Point Prevalence and Predictors in a University Hospital. Int J Environ Res Public Health
437		<b>2019</b> ; 16(2): 194.
438	35.	Toba K, Ouchi Y, Orimo H, et al. Urinary incontinence in elderly inpatients in Japan: a
439		comparison between general and geriatric hospitals. Aging (Milano) 1996; 8(1): 47-54.
440	36.	Bennet J, McCall A. Women Poop. Sometime at work. Get over it. Available at:
441		https://www.nytimes.com/2019/09/17/style/women-poop-at-work.html. Accessed 1
442		December 2020.
443	37.	MacKenzie M. This is how many people refuse to poop at work-Are you one of them?
444		Womens Health. Available at:
445		https://www.womenshealthmag.com/health/a19998266/pooping-at-work/. Accessed 1

446 December 2020.

# **TABLES**

	·		N1				N2	•	E <sup>β</sup>			
Hospital	Collection period	No. of tested samples	% of (+) SARS- CoV-2*	Cq median (IQR)	Cq range <sup>†</sup>	% of (+) SARS- CoV-2*	Cq median (IQR)	Cq range <sup>†</sup>	% of (+) SARS- CoV-2*	Cq median (IQR)	Cq range <sup>†</sup>	
1	August 5 <sup>th</sup> to December 17 <sup>th</sup>	40	62.5	32.5 (30.6- 36.4)	12.5	50	35.3 (33.5- 37.7)	13.5	7.5	35.5 (31.3- 37.3)	12.1	
2	August 5 <sup>th</sup> to December 17 <sup>th</sup>	40	45	31.8- 35.9	8.6	35	35.9 (34.5- 37.8)	9.04	0	-	-	
3A	August 5 <sup>th</sup> to December 17 <sup>th</sup>	39	51.3	32.8 (30.7- 35.6)	11.9	48.7	36.2 (33.2- 41.2)	16.3	12.8	30.6 (28.5- 30.7)	5.7	
3B	October 1 <sup>st</sup> to December 17 <sup>th</sup>	23	91.3	34.6 (33.8- 36.5)	8.3	73.9	39.6 (38.1- 41.7)	9.7	0	-	-	

# **Table 1.** Descriptive statistics of SARS-CoV-2 RNA monitoring among wastewater hospital samples.

3C	to December 17 <sup>th</sup>	23	78.3	36.4 (34.7- 37.1)	11.07	52.2	41.1 (39.7- 41.7)	13.08	4.3	34.9	-
* Percentage	of samples positi	ve for SA	RS-CoV2 (	no. of posit	ive samples	/no. of test	ed samples)				

- 450 <sup>†</sup>Range is the difference between the max and min value for Cq, cycle of quantification.
- $^{\beta}$  E assay was performed for samples collected from August 5<sup>th</sup> to October 29<sup>th</sup>.

Table 2. Correlation analyses between SARS-CoV-2 RNA signal in wastewater from Calgary Hospitals with daily-prevalent cases of
 patients hospitalized with COVID-19 and those incident hospital-acquired cases.

<b>TT</b> •4 1			Cq			Copies/1	ml	Сор	ies/Copies	PMMoV <sup>†</sup>
Hospital	Comparison	r	P-value	95% CI	r	P-value	95% CI	r P-val	P-value	95% CI
	N1 vs N2	0.710	<0.0001	0.511 – 0.836	-	-	-	-	-	-
1	N1 vs prevalent	0.486	0.0027	0.187 – 0.702	0.290	0.0858	-0.0422 – 0.565	0.187	0.2737	-0.150 – 0.486
	N1 vs incident*	0.537	0.0005	0.263 – 0.731	0.279	0.0896	-0.0445 – 0.550	0.277	0.0920	-0.0466 – 0.548
	N1 vs N2	0.762	<0.0001	0.587 – 0.868	-	-	-	-	-	-
2	N1 vs prevalent	0.862	<0.0001	0.742 – 0.929	0.542	0.0008	0.255 – 0.741	0.534	0.0009	0.245 – 0.736
	N1 vs incident*	0.474	0.0030	0.177 – 0.692	0.25 5	0.1273	-0.0750 - 0.535	0.283	0.0900	-0.0455 – 0.556
3A	N1 vs N2	0.792	<0.0001	0.620 – 0.892	-	-	-	-	-	-

	N1 vs prevalent#	0.717	<0.0001	0.481 – 0.856	0.20 2	0.2840	-0.171 – 0.524	0.147	0.4382	-0.225 – 0.482
	N1 vs incident*	0.350	0.0492	0.00201 - 0.623	0.46 3	0.0077	0.136 – 0.699	0.444	0.0109	0.113 – 0.686
	N1 vs N2	0.417	0.0478	0.00565 – 0.708	-	-	-	-	-	-
3B	N1 vs prevalent#	0.139	0.5709	-0.337 – 0.558	0.13 5	0.5821	-0.340 – 0.555	0.139	0.5707	-0.558 – 0.337
	N1 vs incident*	0.0654	0.7783	-0.377 – 0.483	- 0.03 96	0.8645	-0.463 – 0.399	0.187	0.4179	-0.267 – 0.572
	N1 vs N2	0.491	0.0174	0.0987 – 0.751	-	-	-	-	-	-
3C	N1 vs prevalent#	- 0.0929	0.7052	-0.525 – 0.377	0.50 3	0.0282	0.0632 – 0.779	0.479	0.0379	0.0318 – 0.767
	N1 vs incident*	0.266	0.2433	-0.187 – 0.626	- 0.04 81	0.8361	-0.470 – 0.392	0.006 04	0.9793	-0.427 – 0.437

456 \* Average of incident hospital acquired cases (-/+3 days from sample collection).

<sup>†</sup>Relative SARS-CoV2 genomic copies compared to genomic copies of PMMoV.

458 # Prevalent cases at Hospital-3 are reported for the entire facility – as opposed to those cases directly housed in 3A, 3B, 3C.

459 Cq, quantification cycle.

# 460 **Table 3.** SARS-CoV-2 RNA detection in hospital-wastewater samples as a function of proximity

to a declared outbreak.

Hospital	Measurement	Outbreak-free periods vs outbreaks (Median (IQR))	P-value
1	Copies/ml	0 (0-7.9) vs 280 (35-1768)	< 0.0001
I	Copies/Copies PMMoV	0 (0-0.07) vs 0.18 (0.09-1.8)	0.0001
2	Copies/ml	0 (0-0) vs 8 (1.1-17)	0.022
2	Copies/Copies PMMoV	0 (0-0) vs 0.035 (0-0.21)	0.453
34	Copies/ml	0 (0-12) vs 122 (5.9-408)	0.031
511	Copies/Copies PMMoV	0 (0-0.11) vs 0.5 (0.01-10)	0.026
30	Copies/ml	2.4 (0-8.8) vs 26 (1.1-3179)	0.212
50	Copies/Copies PMMoV	0.013 (0-0.08) vs 0.1 (0.0003-6.9)	0.253

462

#### 464 FIGURES LEGENDS

Figure 1. Determination of SARS-CoV-2 RNA in wastewater samples from Hospital-1 and 465 Hospital-2. Relative SARS-CoV-2 genomic copies compared to genomic copies of PMMoV from 466 A) Hospital 1 (August 5<sup>th</sup> to December 17<sup>th</sup>) and B) Hospital 2 (August 5<sup>th</sup> to December 17<sup>th</sup>). 467 Ouantification of SARS-CoV-2 RNA in samples was determined by the N1 (black) and N2 (red) 468 assays. Green line denotes the total daily number of active prevalent cases in the hospital. Orange 469 bars denotes the number of daily hospital-acquired cases. Plots show the average of three technical 470 replicates and error bars represent the standard deviation. Vertical dash lines correspond to days 471 where outbreaks were declared (Table S3), where the number of patients and health care workers 472 involved are indicated at the top each dotted dash line. Asterisk denotes that for a specific outbreak 473 more than one unit was involved. Gray zones denote duration of the outbreak. HA: hospital 474 acquired. Bottom individual boxed areas represent individual samples as Positives (+) = samples 475 where SARS-CoV-2 signal identified with a Cq<40, and negatives (-) had values  $\geq$ 40. Please note 476 that the scale is different in Figure A and B. 477

#### 478 Figure 2. Determination of SARS-CoV-2 RNA in wastewater samples from Hospital-3.

Relative SARS-CoV-2 genomic copies compared to genomic copies of PMMoV from A) Hospital 479 3A (Trauma, Medical & Surgical ICUs, orthopedics surgery and designated COVID-care units) 480 August 5<sup>th</sup> to December 17<sup>th</sup>), B) Hospital 3B (i.e., Main Building, North wing, October 1<sup>st</sup> to 481 482 December 17<sup>th</sup>) and C) Hospital3C (i.e., Main Building South Wing, cancer care building, complex medical care building and hostel/administration building), October 1<sup>st</sup> to December 17<sup>th</sup>). 483 Quantification of SARS-CoV-2 RNA in samples was determined by the N1 (black) and N2 (red) 484 assays. Green line denotes the number of prevalent cases in the hospital. Orange bars denotes the 485 number of daily hospital-acquired cases. Plots show the average of three technical replicates and 486

error bars represent the standard deviation. Vertical dash lines correspond to days where outbreaks 487 were declared (Table S3), where the number of patients and health care workers involved are 488 489 indicated at the top each dotted dash line. Asterisk (\*) denotes the largest outbreak which occurred initially at Hospital 3C prior to instituted monitoring at that site – and reflects the SARS-CoV-2 490 infected patients who were relocated to the designated COVID-19 wards inHospital 3A where it 491 492 was detected by wastewater monitoring. The last case associated with the large outbreak was identified October 19th. Gray zones denote duration of the outbreak. HA: hospital acquired. Bottom 493 individual boxed areas represent individual samples as Positives (+) = samples where SARS-CoV-494 2 signal identified with a Cq<40, and negatives (-) had values  $\geq$ 40. Please note that the scale is 495 different from A, B and C figures. 496

### 498 FIGURES

### 499 Figure 1



500

## 502 Figure 2



503